Conservative versus radical therapy of prostate cancer: How have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?

被引：5

作者：

Bagnall, S ^{[1
]}

Klotz, L ^{[1
]}

机构：

[1] Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 05期

关键词：

D O I：

10.1016/S0093-7754(03)00348-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：587 / 595

页数：9

共 98 条

[1] DEFERRED TREATMENT IN CLINICALLY LOCALIZED PROSTATIC-CARCINOMA [J].

ADOLFSSON, J ;

CARSTENSEN, J ;

LOWHAGEN, T .

BRITISH JOURNAL OF UROLOGY, 1992, 69 (02) :183-187

[2]

Adusumilli Saroja, 2002, Semin Urol Oncol, V20, P192, DOI 10.1053/suro.2002.35333

[3] Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [J].

Albertsen, PC ;

Hanley, JA ;

Gleason, DF ;

Barry, MJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :975-980

[4] LONG-TERM SURVIVAL AND MORTALITY IN PROSTATE-CANCER TREATED WITH NONCURATIVE INTENT [J].

AUS, G ;

HUGOSSON, J ;

NORLEN, L .

JOURNAL OF UROLOGY, 1995, 154 (02) :460-465

[5] EARLY CARCINOMA OF PROSTATE - COMPARISON OF STAGES A AND B [J].

BARNES, R ;

HIRST, A ;

ROSENQUIST, R .

JOURNAL OF UROLOGY, 1976, 115 (04) :404-405

[6]

BASERGA R, 1995, CANCER RES, V55, P249

[7]

BATTISTINI B, 1993, LAB INVEST, V68, P600

[8] Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer [J].

Bauer, JJ ;

Sesterhenn, IA ;

Mostofi, FK ;

McLeod, DG ;

Srivastava, S ;

Moul, JW .

JOURNAL OF UROLOGY, 1996, 156 (04) :1511-1516

[9] Bloodborne biomolecular markers in prostate cancer development and progression [J].

Bok, RA ;

Small, EJ .

NATURE REVIEWS CANCER, 2002, 2 (12) :918-926

[10]

BOOKSTEIN R, 1993, CANCER RES, V53, P3369

← 1 2 3 4 5 6 7 8 9 10 →